The Journal of Rheumatology · 2012 · 66 citations · 37 references
MedicineClinical SciencesInternal MedicineGastroenterologyRheumatologySystemic PathologyFunctional Gastrointestinal DisordersGastrointestinal AssessmentSystemic SclerosisDisease DurationDisease SubsetsQuestionnaire AdministrationWell-being
OBJECTIVE: To assess the effect of gastrointestinal (GI) manifestation on the quality of life in patients with systemic sclerosis (SSc). METHODS: The University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2 questionnaire was completed by 87 consecutive patients with SSc attending the scleroderma clinic at a single center. Their clinical features and current therapies were recorded; 100 patients with rheumatologic disorders other than SSc were used as controls. Individual scores were compared between SSc and controls, and between SSc subgroups. RESULTS: Of 87 patients, 76 (90%) were women. Median age was 55 years and disease duration 105 months. Thirty-three (38%) had diffuse and 54 (62%) had limited SSc. Patients with SSc had a higher score than controls in all domains (p < 0.05). Numbers of patients who responded positively to individual questionnaire components are as follows: any GI symptom 86 (99%), reflux 77 (89%), distension 73 (84%), soilage 19 (22%), diarrhea 44 (51%), constipation 51 (59%), well-being 43 (49%), and social 43 (49%). There was no difference between the scores of patients with diffuse and limited disease subtypes. The use of calcium channel blockers did not significantly increase the constipation score (p = 0.99). Patients who responded positively to the reflux, distension, diarrhea, and constipation domains had lower scores in the well-being and social domains. CONCLUSION: GI manifestations, especially fecal incontinence (affecting 22% of patients), have a negative influence on the quality of life of patients with SSc. There was no difference between SSc disease subtypes.
37
A New Measure of Health Status for Clinical Trials in Inflammatory Bowel Disease
Alba Mitchell, E. Jan Irvine, Joel Singer et al. · Gastroenterology · 1989 · 1.2K citations · Full text
A new measure of health status for clinical trials in inflammatory bowel disease
Gordon Guyatt, Alba Mitchell, E. Jan Irvine et al. · Gastroenterology · 1989 · 736 citations · Full text
Otylia Kowal‐Bielecka, Robert Landewé, Jérôme Avouac et al. · Annals of the Rheumatic Diseases · 2009 · 617 citations · Full text